Sertraline (SSRIs) and Upper gastrointestinal bleeding: is the FAERS signal real?
Sertraline (SSRIs) ↔ Upper gastrointestinal bleeding
SSRIs such as sertraline impair platelet serotonin uptake, and because platelets depend on serotonin for aggregation, this produces a modestly increased bleeding tendency — most clearly seen as upper gastrointestinal bleeding, especially when combined with NSAIDs, aspirin, or anticoagulants. The risk is a class effect, is not dose-specific in a simple way, and is an important drug-interaction consideration. The 361 co-reports (PRR 3.9) reflect both the real association and the enormous number of people taking SSRIs.
Regulatory basis: sertraline/SSRI labelling warnings on abnormal bleeding, especially with NSAIDs/anticoagulants. Established SSRI-GI-bleeding observational literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Bleeding occurs during treatment and resolves after withdrawal |
| Strength | partial | PRR 4 on a moderate co-report count |
| Consistency | met | Reproduced across SSRI cohorts and case-control studies |
| Specificity | partial | A class effect across SSRIs, amplified by other bleeding-risk drugs |
| Biological gradient | partial | Risk rises with age, and with NSAID, aspirin, or anticoagulant co-therapy |
| Plausibility | met | Impaired platelet serotonin uptake reduces platelet aggregation |
| Coherence | met | Coheres with the labelled bleeding/interaction warnings |
| Experiment | partial | Observational; no randomized trial has tested bleeding outcomes |
| Analogy | met | Analogous to bleeding risk with other SSRIs and serotonin-reuptake-inhibiting drugs |
This page's own qualitative read, not an automated/citation-gated assessment.